|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2010-12-16
|
|
pubmed:abstractText |
Belatacept is associated with better renal function and an improved cardiovascular/metabolic risk profile versus cyclosporine in kidney transplant recipients. The current analysis examined pooled safety data for belatacept versus cyclosporine used in combination with basiliximab, mycophenolate mofetil, and steroids.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1534-6080
|
|
pubmed:author |
pubmed-author:AgarwalMamtaM,
pubmed-author:ApanovitchAnne MarieAM,
pubmed-author:CharpentierBernardB,
pubmed-author:GrinyóJosepJ,
pubmed-author:GujrathiSheilaS,
pubmed-author:LarsenChristian PCP,
pubmed-author:PestanaJosé MedinaJM,
pubmed-author:Reyes-AcevedoRafaelR,
pubmed-author:ThomasDolcaD,
pubmed-author:VanrenterghemYvesY,
pubmed-author:VincentiFlavioF
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
27
|
|
pubmed:volume |
90
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1521-7
|
|
pubmed:dateRevised |
2011-3-28
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
An integrated safety profile analysis of belatacept in kidney transplant recipients.
|
|
pubmed:affiliation |
Division of Nephrology, University Hospital of Bellvitge, Barcelona, Spain. jgrinyo@bellvitgehospital.cat
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
